CD93在慢性髓性白血病干细胞上表达并标识TKI治疗后持续存在的静息细胞群
该研究显示CD93在lin-CD34+CD38-CD90+慢性髓性白血病(CML)干细胞群上一致且选择性表达,该群在体外和患者来源异种移植模型中表现出更强的干细胞特征和植入能力,而CD93-的CML干/祖细胞群不能植入。通过批量和单细胞分析,研究确认了该群的静息特征,并证明其在停用酪氨酸激酶抑制剂(TKI)后分子复发的CML患者样本中持续存在。结果提示CD93可能有助于判断TKI反应不佳者。
要点
- CD93在lin-CD34+CD38-CD90+ CML干细胞群上一致且选择性表达。
- CD93+ CML干细胞群具有更强干细胞特征和植入能力,CD93-群不能植入。
- CD93+静息CML干细胞在停用TKI后分子复发的患者样本中持续存在。
核心结论
- CD93在lin-CD34+CD38-CD90+ CML干细胞群上一致且选择性表达,该群具有干细胞特征和静息特性。
- CD93+ CML干细胞群在停用TKI后分子复发的患者样本中持续存在,可能有助于判断TKI反应不佳者。
研究设计与样本
- 研究对lin-CD34+CD38-CD90+ CML干细胞群进行CD93表达分析,并开展体外和体内实验及患者来源异种移植模型。
- 研究对选定干细胞和细胞存活相关基因进行批量和单细胞分析,并检测停用TKI后分子复发的CML患者样本。
主要发现
- CD93在lin-CD34+CD38-CD90+ CML干细胞群上一致且选择性表达。
- 与CD93- CML干/祖细胞群相比,CD93+群表现出更强的干细胞特征和稳健植入,而CD93-群不能植入。
- CD93+ CML干细胞群具有静息特征,并在停用TKI后分子复发的患者样本中持续存在。
临床怎么用
- CD93可能作为识别具有干细胞特征和静息特性的CML干细胞群的标志物。
- CD93可能有助于判断TKI反应不佳者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite targeted therapeutic approaches, BCR-ABL-independent mechanisms exist which sustain the survival of leukemic stem cells (LSCs). Although other markers of a primitive CML LSC population have been identified in the preclinical setting, only CD26 appears to offer clinical utility. Here we demonstrate consistent and selective expression of CD93 on a lin-CD34+CD38-CD90+ CML LSC population and show in vitro and in vivo data to suggest increased stem cell characteristics, as well as robust engraftment in patient-derived xenograft models in comparison with a CD93- CML stem/progenitor cell population, which fails to engraft. Through bulk and single-cell analyses of selected stem cell and cell survival-specific genes, we confirmed the quiescent character and demonstrate their persistence in a population of CML patient samples who demonstrate molecular relapse on TKI withdrawal. Taken together, our results identify that CD93 is consistently and selectively expressed on a lin-CD34+CD38-CD90+ CML LSC population with stem cell characteristics and may be an important indicator in determining poor TKI responders.
引用
- Kinstrie R, Horne GA, Morrison H, et al. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia. 2020. PMID: 31896780. doi:10.1038/s41375-019-0684-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。